Comparing Paradigm Medical Industries (OTCMKTS:PDMI) & Pulse Biosciences (NASDAQ:PLSE)

Pulse Biosciences (NASDAQ:PLSE) and Paradigm Medical Industries (OTCMKTS:PDMI) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership.

Profitability

This table compares Pulse Biosciences and Paradigm Medical Industries’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pulse Biosciences	N/A	-86.67%	-73.61%
Paradigm Medical Industries	N/A	N/A	N/A

Analyst Recommendations

This is a summary of current recommendations and price targets for Pulse Biosciences and Paradigm Medical Industries, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulse Biosciences	1	0	3	0	2.50
Paradigm Medical Industries	0	0	0	0	0.00

Pulse Biosciences currently has a consensus target price of $30.67, suggesting a potential upside of 9.10%. Given Pulse Biosciences’ stronger consensus rating and higher possible upside, analysts plainly believe Pulse Biosciences is more favorable than Paradigm Medical Industries.

Risk & Volatility

Pulse Biosciences has a beta of 1.65, suggesting that its stock price is 65% more volatile than the S&P 500. Comparatively, Paradigm Medical Industries has a beta of -1.62, suggesting that its stock price is 262% less volatile than the S&P 500.

Earnings and Valuation

This table compares Pulse Biosciences and Paradigm Medical Industries”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulse Biosciences	$350,000.00	5,558.55	-$72.78 million	($1.10)	-25.55
Paradigm Medical Industries	N/A	N/A	N/A	N/A	N/A

Paradigm Medical Industries has lower revenue, but higher earnings than Pulse Biosciences.

Institutional and Insider Ownership

77.0% of Pulse Biosciences shares are owned by institutional investors. 74.0% of Pulse Biosciences shares are owned by company insiders. Comparatively, 11.1% of Paradigm Medical Industries shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Pulse Biosciences beats Paradigm Medical Industries on 7 of the 9 factors compared between the two stocks.

About Pulse Biosciences

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.

About Paradigm Medical Industries

Paradigm Medical Industries, Inc. develops, manufactures, sells, and markets medical devices for the early detection of glaucoma and other eye disorders in the United States. The company offers P-2000 biometric analyzer A-scans and P-2500 A-scans/pachymeters; P2700 A/B and P37-II A/B scans; blood flow analyzers for the detection and management of glaucoma and other retinal vascular disorders; P2200 pachymeter and P-2500 A-scan/pachymeters; and LD 500 and LD700 autoperimeters. It also provides corneal topographers, such as PARAVUE 300 for diagnostic and contact lens applications, as well as SURVEYOR 500 for cornea and anterior segment; PARAMAX, which analyzes the functionality of ganglion cells and identifies glaucoma suspects; P60 and P60 ACI ultrasound biomicroscopes; and PARACAM 1000, a non-contact endothelial microscope, as well as software and accessories. The company was founded in 1989 and is based in Salt Lake City, Utah.